Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating income | -$36.2M | -$83.1M | -$125M |
| Net income | -$34.8M | -$78.3M | -$111M |
| EPS (diluted) | -$23.10 | -$3.78 | -$2.86 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$27.2M | -$64.8M | -$87.5M |
| Capital expenditures | $1.64M | $2.40M | $616K |
| Free cash flow | -$28.8M | -$67.2M | -$88.1M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $70.2M | $56.8M | $52.6M |
| Total assets | $155M | $315M | $512M |
| Total liabilities | $14.5M | $9.51M | $27.8M |
| Shareholders' equity | -$25.6M | $305M | $485M |
| Retained earnings | -$45.4M | -$124M | -$235M |
| Shares (wtd avg diluted) | 1.51M | 20.7M | 38.9M |
Every figure is extracted from Rapport Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.